Business Context and Reporting Period
Lumexa Imaging Holdings, Inc. (LMRI) filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company is one of the largest national providers of diagnostic imaging services, operating 188 outpatient imaging centers across 13 states. Lumexa completed its Initial Public Offering (IPO) in December 2025, listing on the Nasdaq Global Select Market. The company operates through two segments: Outpatient Imaging Centers and Professional Services. It utilizes a joint venture model with health systems, accounting for 86 centers under the equity method and consolidating 102 centers.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Consolidated Revenue | $1.023 billion | $948.9 million |
| System-Wide Revenue | $1.111 billion (implied) | $1.027 billion (implied) |
| Net Loss | $(47.1) million | $(94.1) million |
| Adjusted EBITDA | $230.2 million | $200.8 million |
| Adjusted EBITDA Margin | 22.5% | 21.2% |
| Operating Cash Flow | $17.1 million | $40.7 million |
| Total Debt Outstanding | $825.0 million | $1.2 billion |
| Cash and Cash Equivalents | $58.8 million | $26.1 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 7.8% year-over-year, driven by a 7.7% increase in consolidated same-center revenue (5.4% volume growth and 2.2% net revenue per scan growth). System-wide revenue grew 8.2%.
- Profitability: Net loss improved significantly from $94.1 million in 2024 to $47.1 million in 2025. Adjusted EBITDA increased 14.6% to $230.2 million.
- Debt Refinancing: In December 2025, the company refinanced its term loan, reducing the principal balance from $1.2 billion to $825.0 million and lowering the interest rate spread from SOFR + 4.75% to SOFR + 3.00%. This resulted in a $13.5 million loss on extinguishment of debt but reduced annual interest expense.
- Capital Structure: The company raised approximately $427 million in net proceeds from its IPO in December 2025. A significant portion ($406.4 million) was used to pay down existing debt.
- Expense Increases: General and administrative expenses rose 28.6% to $90.5 million, primarily due to stock-based compensation vesting upon the IPO and increased legal, professional, and IT costs associated with becoming a public company.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to sustain operations with existing capital resources and cash flow. Growth strategies include same-center organic growth, de novo center expansion (targeting $1.0M–$3.0M Adjusted EBITDA contribution per center), and acquisitions. The company is actively implementing third-party AI solutions to improve efficiency and reduce labor costs.
Material Risks and Contingencies:
- Internal Control Weaknesses: The company identified material weaknesses in internal control over financial reporting that remained unremediated as of December 31, 2025. These include deficiencies in the control environment, risk assessment, revenue accounting controls, segregation of duties, and IT general controls.
- Reimbursement Risk: Revenue is heavily dependent on third-party payors (58% commercial, 29% government). Reductions in reimbursement rates or changes in coverage policies could materially harm financial results.
- Regulatory Compliance: The company faces significant regulatory risks regarding the Anti-Kickback Statute, Stark Law, and HIPAA. Non-compliance could result in penalties, exclusion from government programs, or reputational damage.
- Cybersecurity: The company experienced a data breach in 2021 and faces ongoing risks from ransomware and cyberattacks that could disrupt operations.
- Joint Venture Dependence: A significant portion of the business operates through joint ventures with health systems. Termination of these agreements or failure to maintain synergistic relationships could negatively impact the business.
Investor Verification Checklist
- Remediation of Internal Controls: Verify the progress and timeline for remediation of the disclosed material weaknesses in internal controls over financial reporting.
- Debt Covenants: Confirm compliance with financial covenants under the Amended Credit Agreement, specifically the net leverage ratio if revolving credit exposure exceeds 40%.
- Reimbursement Trends: Monitor changes in commercial and government reimbursement rates and the impact of the "One Big Beautiful Bill Act" on Medicaid reimbursement.
- Joint Venture Performance: Review the financial performance of unconsolidated affiliates (specifically BTDI), which contributed $72.1 million to equity in earnings.
- AI Implementation ROI: Assess the tangible impact of AI implementation on labor costs and operational efficiency as projected by management.